Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib

Table 2 Characteristics of transarterial radioembolization procedures

	All procedures (n = 169)	TARE_alone (n = 63)	TARE_sorafenib (n = 81)	TARE_no_sorafenib (n = 25)
LSF, %	6.0 (0.8-30.4)	4.6 (1.0-26.4)	6.1 (0.8-30.4)	6.3 (2.0-13.6)
Lung mean dose, Gy1	8.2 (0.3-29.7)	4.7 (0.3-29.2)	10.1 (0.5-29.7)	11.2 (2.0-29.2)
Mean dose to treated liver volume, Gy1	110 (80-135)	110 (80-135)	110 (80-135)	110 (80-135)
Interval between Tc-99m MAA and TARE, d1	20 (0-125)	21 (0-1252)	17 (0-44)	21 (10-34)
Administered activity, GBq	2.5 (0.3-8.1)	1.7 (0.3-6.3)	2.9 (0.6-8.1)	2.7 (0.8-5.9)
TARE approach, n (%)
Whole liver3	47 (27.8)	16 (25)	25 (31)	6 (24)
Lobar + segment	22 (13)	4 (6)	15 (18)	3 (12)
Lobar	66 (39.1)	23 (37)	30 (37)	13 (52)
Multiple segments	23 (13.6)	13 (21)	7 (9)	3 (12)
Single segment	11 (6.5)	7 (11)	4 (5)	0

¹Mean absorbed doses values for each treatment session.

²The outliner interval of 125 d was from a single patient whose initial treatment plan was a whole liver treatment with sequential lobar infusion three weeks apart. His subsequent left lobar treatment was delayed for months because of his medical conditions. Administered activity of left lobar approach was calculated using the original Tc-99m MAA plan and re-evaluation CT scan performed prior to left lobar treatment.

³Consisted of single infusion (n = 19), separate infusion (n =24) and sequential infusion (n = 4).

Values represent median (range) unless otherwise stated. TARE: Transarterial radioembolization; Tc-99m MAA: The technetium-99m macro aggregated albumin.